Practicing aggressive innovation.

Bringing high-value therapies to the patients who need them requires a keen eye for potential and a dedication to accelerating the development of late-stage assets. We have both.
We are always interested in collaborating with development, manufacturing, and commercialization partners to bring innovative products to patients living with rare diseases.

Keeping the flow going.

Therapeutic AreaMetabolic GeneticsEndocrinologyPediatricET-400EndocrinologyZENEO®Needle-FreeAutoinjectorEndocrinologyET-600Metabolic GeneticsMetabolic GeneticsEvaluationCMCDevelopmentPhase III/BA/BE StudyA/NDASubmission2024TBD2025CommercialNitisinone Capsulesfor oral useBetaineanhydrous for oral solutionCMC = Chemistry, Manufacturing, Controls; BA = Bioavailability; BE = Bioequivalence; NDA = New Drug Application; ANDA = Abbreviated New Drug Application

Interested in a partnership?

Let’s start the conversation.